Swedish registry questions superiority of bivalirudin over heparin in patients undergoing PCI for NSTE-ACS
22 May 2013
The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol
5 February 2013
The Medicines Co settles with APP over Angiomax
24 January 2012
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
The Medicines Company gets EU appro for Angiox for heart attack patients undergoing emergency procedures
2 December 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Medicines Co forced to end CHAMPION trial
15 May 2009
TMC's 2008 net loss narrows 53% to $8.5M
2 March 2009
Angiomax reduces hospital costs, says study from producer TMC
24 November 2008
US FDA rejects new Angiomax ACS use
9 June 2008
Angiomax improves net clinical outcomes
7 April 2008
EC clears Angiox for ACS with UA or NSTEMI
4 February 2008
CHMP "thumbs up" for Angiox extension
26 November 2007
Biogen forecasts 2007 sales growth of 16-18%, and EPS to increase 20% a year to 2010
17 September 2007
Angiox impresses in ACS patients undergoing PCI
10 September 2007
The Med Co swings to $3M profit in 1st qtr
30 April 2007
Stock Commentary - New York week to Nov 27
4 December 2006
Angiomax cuts risk of ACS major bleeding 47%
4 December 2006
Strong data for TMC's Angiomax vs heparins
20 March 2006
TMC enrolls patients for ACUITY trial of Angiomax
12 December 2005
USA's TMC posts 39% sales growth
22 April 2005
Cardiac benefits reported with Millennium's Integrilin
21 March 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Positive results for Medicure's novel antithrombotic
7 March 2005
Medicines Co's Angiox launched in UK
13 December 2004
The Medicines Co sees 3rd-qtr sales rocket 77%
25 October 2004
EC clears Medicines Co's Angiox
4 October 2004
Guilford plans two new trials for Aggrastat
30 August 2004
Medicines Co's Angiox on track in EU
5 July 2004
sNDA filed with the FDA for Angiomax
11 August 2003
The Medicines Co offers 4M shares
10 March 2003
TMC and CSL form Angiomax agreement
14 January 2002
Angiomax reduces death in HERO-2 trial
3 September 2001
Medicines Co enters deal with Ferrer
2 July 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
TMC's Angiomax approved in USA
19 December 2000
The Medicines Co gets partial FDA backing
18 May 2000
1st Angiomax approval in New Zealand
4 November 1999
The Medicines Co Start Hirulog Phase III Trial
8 December 1998
FDA Rejects The Medicine Company's Hirulog
29 October 1998
Date Set For Ziagen Review In USA
8 October 1998
TMC Completes $36M Private Placement
10 September 1998
TMC Acquires Triptan From Immunotech
19 August 1998
UK Launch For Refludan; Angina Filing By End-98?
19 March 1998
Hirulog Dossier "Filable" Says FDA
25 February 1998
Biogen Licenses Hirulog Rights To The Medicine Company
26 March 1997
Showing 1-48 of 48 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
